305 related articles for article (PubMed ID: 30253191)
1. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
[TBL] [Abstract][Full Text] [Related]
2. FOXF1 Induces Epithelial-Mesenchymal Transition in Colorectal Cancer Metastasis by Transcriptionally Activating SNAI1.
Wang S; Yan S; Zhu S; Zhao Y; Yan J; Xiao Z; Bi J; Qiu J; Zhang D; Hong Z; Zhang L; Huang C; Li T; Liang L; Liao W; Jiao H; Ding Y; Ye Y
Neoplasia; 2018 Oct; 20(10):996-1007. PubMed ID: 30189360
[TBL] [Abstract][Full Text] [Related]
3. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Burgermeister E; Battaglin F; Eladly F; Wu W; Herweck F; Schulte N; Betge J; Härtel N; Kather JN; Weis CA; Gaiser T; Marx A; Weiss C; Hofheinz R; Miller IS; Loupakis F; Lenz HJ; Byrne AT; Ebert MP
EBioMedicine; 2019 Jul; 45():139-154. PubMed ID: 31300350
[TBL] [Abstract][Full Text] [Related]
4. DHX32 Promotes Angiogenesis in Colorectal Cancer Through Augmenting β-catenin Signaling to Induce Expression of VEGFA.
Lin H; Fang Z; Su Y; Li P; Wang J; Liao H; Hu Q; Ye C; Fang Y; Luo Q; Lin Z; Pan C; Wang F; Zhang ZY
EBioMedicine; 2017 Apr; 18():62-72. PubMed ID: 28330603
[TBL] [Abstract][Full Text] [Related]
5. miR-622 inhibits angiogenesis by suppressing the CXCR4-VEGFA axis in colorectal cancer.
Fang Y; Sun B; Wang J; Wang Y
Gene; 2019 May; 699():37-42. PubMed ID: 30851425
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
Mésange P; Poindessous V; Sabbah M; Escargueil AE; de Gramont A; Larsen AK
Oncotarget; 2014 Jul; 5(13):4709-21. PubMed ID: 25015210
[TBL] [Abstract][Full Text] [Related]
11. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression.
Wang R; Ma Y; Zhan S; Zhang G; Cao L; Zhang X; Shi T; Chen W
Cell Death Dis; 2020 Jan; 11(1):55. PubMed ID: 31974361
[TBL] [Abstract][Full Text] [Related]
13. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2.
Chen X; Zeng K; Xu M; Liu X; Hu X; Xu T; He B; Pan Y; Sun H; Wang S
Cell Death Dis; 2019 Feb; 10(2):131. PubMed ID: 30755600
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.
Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y
Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802
[TBL] [Abstract][Full Text] [Related]
17. MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis.
Zhou Q; Zhu Y; Wei X; Zhou J; Chang L; Sui H; Han Y; Piao D; Sha R; Bai Y
Cell Death Dis; 2016 Oct; 7(10):e2413. PubMed ID: 27735951
[TBL] [Abstract][Full Text] [Related]
18. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer.
Lee SJ; Lee I; Lee J; Park C; Kang WK
Br J Cancer; 2014 Jul; 111(3):497-505. PubMed ID: 24945998
[TBL] [Abstract][Full Text] [Related]
19. FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway.
Feng H; Jin Z; Liang J; Zhao Q; Zhan L; Yang Z; Yan J; Kuang J; Cheng X; Qiu W
Oncogene; 2021 Oct; 40(42):6115-6129. PubMed ID: 34489549
[TBL] [Abstract][Full Text] [Related]
20. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB.
Cheng X; Jin Z; Ji X; Shen X; Feng H; Morgenlander W; Ou B; Wu H; Gao H; Ye F; Zhang Y; Peng Y; Liang J; Jiang Y; Zhang T; Qiu W; Lu X; Zhao R
Int J Cancer; 2019 Jul; 145(1):179-191. PubMed ID: 30650178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
